Filament Health, a subsidiary of Rhelion Life Sciences, will supply its patented psilocybin drug candidate PEX010 to a University of California, San Francisco (UCSF) Phase 2 clinical trial. The trial, starting November 2026, will test whether a single dose of psilocybin can reduce methamphetamine use in people living with HIV, a condition currently without FDA-approved medication. The study will enroll 30 participants and use a quadruple-blind design to assess safety, feasibility, and effectiveness. This research is significant as methamphetamine use worsens health outcomes in HIV patients and no approved treatments exist for methamphetamine use disorder.
Rhelion Life Sciences' subsidiary Filament Health is the subject of this update. For readers following the health sector, here is Pluang's market snapshot as of Oct 08, 2026 18:43 WIB: Of 128 priced US health stocks, 29 rose and 91 fell today. Notable movers include DNA at USD 11.07 with a -3.49% change, MESO at USD 13.48 with a -3.30% change, and SANA at USD 2.80 with a +2.94% change and 73% buy order activity.
Dividend 15 Split Corp. has renewed its at-the-market (ATM) equity program, allowing it to issue shares to the public at prevailing market prices until November 7, 2028. This program replaces the previous one that ended in 2025 and enables the compan...
Fieldstone Bio, a synthetic biology company, was selected for the Mining Tech Accelerator program by Founders Factory and Rio Tinto. The program supports innovative technologies that improve mineral exploration and extraction, providing Fieldstone wi...
Beam Global has signed a definitive agreement to acquire ScoutDI, a company specializing in drone technology and AI-powered inspection software. The acquisition will enable Beam to manufacture ScoutDI's drone systems in the US and Europe, targeting i...
Grabar Law Office is investigating shareholder claims against four companies—Aardvark Therapeutics, Coastal Financial Corporation, Erasca, Inc., and New Era Energy & Digital—for alleged securities violations and breaches of fiduciary duties. The clai...
Visa Canada's data reveals that the Toronto International Film Festival (TIFF) 2026 increased visitor spending by 12% compared to 2025, with international visitors spending about 40% more than Canadian cardholders. The festival attracted visitors mai...
